JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.
B Colleoni1, S Paternot1, J M Pita1
1WELBIO, Institute of Interdisciplinary Research (IRIBHM) and ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles, Brussels, Belgium.
Oncogene
|April 4, 2017
Summary
New research reveals that c-Jun N-terminal kinases (JNKs) directly activate cyclin D-CDK4 complexes, challenging previous models of cell cycle regulation and cancer. This finding highlights JNKs as key players in cell proliferation control.
Area of Science:
- Cell Biology
- Molecular Oncology
- Signal Transduction
Background:
- Cyclin D-CDK4/6 complexes are crucial regulators of cell cycle progression, and their deregulation is implicated in cancer.
- Previously, cyclin H-CDK7-Mat1 (CAK) was considered the primary CDK-activating kinase, but its constitutive activity posed questions about regulated CDK4 activation.
- Specific proline at CDK4 (P173) suggested a distinct activation mechanism compared to CDK6 and CDK1/2.
Purpose of the Study:
- To identify the specific kinases responsible for the activating phosphorylation of CDK4 at T172.
- To investigate the role of proline-directed kinases, particularly JNKs, in cyclin D-CDK4 activation.
- To elucidate the interplay between JNKs, CDK4, and p21 in regulating cell proliferation.
Main Methods:
- Investigated the kinase activity of JNKs, ERK1/2, and CAK on cyclin D-CDK4 complexes.
- Utilized site-directed mutagenesis to assess the role of p21 phosphorylation sites (S130, T57) in CDK4 activation.
- Employed JNK inhibitors and chemical genetics in MEFs (mouse embryonic fibroblasts) to confirm JNK2 involvement.
Main Results:
- JNKs, but not ERK1/2 or CAK, were identified as direct activating kinases for p21-inactivated cyclin D-CDK4.
- JNKs and ERK1/2 phosphorylated p21 at S130 and T57, though these sites were not essential for JNK-mediated CDK4 phosphorylation.
- JNK inhibition specifically blocked cyclin D1-CDK4-p21 activation in tumor cells, while cyclin D3-CDK4/p27 activation remained unaffected.
Conclusions:
- JNKs are key activating kinases for cyclin D1-CDK4 complexes when bound to p21.
- JNKs can independently phosphorylate both CDK4 and p21, suggesting a dual role in regulating this complex.
- These findings challenge the established view of CDK activation and highlight JNKs as potential therapeutic targets in specific cancers.
Related Concept Videos
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...